FONAR (FONR) 10-Q 19 Feb 25 2025 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Dec. 31, 2024	Feb. 03, 2025
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2024
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2025
Current Fiscal Year End Date	--06-30
Entity File Number	0-10248
Entity Registrant Name	FONAR CORPORATION
Entity Central Index Key	0000355019
Entity Tax Identification Number	11-2464137
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	110 Marcus Drive
Entity Address, City or Town	Melville
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	11747
City Area Code	631
Local Phone Number	694-2929
Title of 12(b) Security	Common Stock, $.0001 par value
Trading Symbol	FONR
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Common Class B [Member]
Entity Common Stock, Shares Outstanding		146
Common Class C [Member]
Entity Common Stock, Shares Outstanding		382,513
Preferred Class A [Member]
Entity Common Stock, Shares Outstanding		313,438
Common Stock [Member]
Entity Common Stock, Shares Outstanding		6,203,465

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Dec. 31, 2024	Jun. 30, 2024
Current Assets:
Cash and cash equivalents	$ 53,583	$ 56,341
Short-term investments	121	136
Accounts receivable – net of allowance for credit losses of $273 and $166 at December 31, 2024 and June 30, 2024, respectively	3,390	4,035
Accounts receivable _ related party	60
Medical receivable – net	23,496	23,992
Management and other fees receivable – net of allowance for credit losses of $12,663 and $12,370 at December 31, 2024 and June 30, 2024, respectively	42,485	41,954
Management and other fees receivable – related medical practices – net of allowance for credit losses of $6,989 and $6,110 at December 31, 2024 and June 30, 2024, respectively	9,677	9,865
Inventories	2,858	2,715
Prepaid expenses and other current assets	1,962	1,286
Total Current Assets	137,632	140,324
Accounts receivable – long term	724	830
Deferred income tax asset	6,113	7,223
Property and equipment – net	19,270	18,709
Note receivable – related party	607	581
Right-of-use-asset – operating leases	34,946	38,428
Right-of-use-asset – financing lease	496	531
Goodwill	4,269	4,269
Other intangible assets – net	3,407	2,870
Other assets	493	481
Total Assets	207,957	214,246
Current Liabilities:
Current portion of long-term debt	49	47
Accounts payable	953	1,856
Other current liabilities	3,912	7,941
Unearned revenue on service contracts	3,413	3,870
Unearned revenue on service contracts – related party	55
Operating lease liabilities _ current portion	3,259	3,474
Financing lease liability _ current portion	244	226
Customer deposits	357	443
Total Current Liabilities	12,242	17,857
Long-Term Liabilities:
Unearned revenue on service contracts	1,050	1,175
Deferred income tax liability	371	371
Due to related party medical practices	93	93
Operating lease liabilities – net of current portion	34,927	37,468
Financing lease liability – net of current portion	290	395
Long-term debt, less current portion	7	67
Other liabilities	26	32
Total Long-Term Liabilities	36,764	39,601
Total Liabilities	49,006	57,458
EQUITY:
Paid-in capital in excess of par value	178,758	180,608
Accumulated deficit	(8,525)	(13,624)
Treasury stock, at cost – 4 shares of common stock at December 31, 2024 and 45 shares of common stock at June 30, 2024	(395)	(1,017)
Total FONAR Corporation’s Stockholders’ Equity	169,839	165,968
Noncontrolling interests	(10,888)	(9,180)
Total Equity	158,951	156,788
Total Liabilities and Equity	207,957	214,246
Class A Non Voting Preferred Stock [Member]
EQUITY:
Preferred stock value	0	0
Preferred Stock [Member]
EQUITY:
Preferred stock value	0	0
Common Stock [Member]
EQUITY:
Common stock value	1	1
Common Class B [Member]
EQUITY:
Common stock value	0	0
Common Class C [Member]
EQUITY:
Common stock value	$ 0	$ 0

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2024	Jun. 30, 2024
Allowance for Doubtful Accounts, Premiums and Other Receivables	$ 273	$ 166
[custom:ManagementAndOtherReceivableAllowancesForDoubtfulAccounts-0]	12,663	12,370
[custom:RelatedPartyReceivableAllowancesForDoubtfulAccounts-0]	$ 6,989	$ 6,110
Treasury Stock, Common, Shares	4,000	45,000
Class A Non Voting Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share		$ 0.0001
Preferred Stock, Shares Authorized		453,000
Preferred Stock, Shares Outstanding		313,000
Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share		$ 0.001
Preferred Stock, Shares Authorized		567,000
Preferred Stock, Shares Outstanding		0
Common Stock [Member]
Common Stock, Par or Stated Value Per Share		$ 0.0001
Common Stock, Shares Authorized		8,500,000
Common Stock, Shares, Issued	6,207,000	6,373,000
Common Stock, Shares, Outstanding	6,203,000	6,328,000
Common Class B [Member]
Common Stock, Par or Stated Value Per Share		$ 0.0001
Common Stock, Shares Authorized		227,000
Common Stock, Shares, Outstanding		146
Common Class C [Member]
Common Stock, Par or Stated Value Per Share		$ 0.0001
Common Stock, Shares Authorized		567,000
Common Stock, Shares, Outstanding		383,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
REVENUES
Patient fee revenue – net of contractual allowances and discounts	$ 7,944	$ 8,221	$ 15,431	$ 16,896
Product sales	25	55	145	219
Service and repair fees	1,759	1,778	3,751	3,643
Service and repair fees _ related parties	45	28	90	55
Management and other fees	12,189	12,316	24,518	24,436
Management and other fees _ related medical practices	2,988	2,988	5,975	5,975
Total Revenues – Net	24,950	25,386	49,910	51,224
COSTS AND EXPENSES
Costs related to patient fee revenue	4,623	4,602	9,269	9,029
Costs related to product sales	221	302	442	405
Costs related to service and repair fees	938	784	2,029	1,633
Costs related to service and repair fees _ related parties	28	12	96	25
Costs related to management and other fees	7,801	7,208	15,111	14,231
Costs related to management and other fees – related medical practices	1,601	1,590	3,174	3,109
Research and development	376	416	683	883
Selling, general and administrative expenses	6,927	5,587	12,065	10,453
Total Costs and Expenses	22,515	20,501	42,869	39,768
INCOME FROM OPERATIONS	2,435	4,885	7,041	11,456
Other income and (expenses)
Interest Expense	(6)	(10)	(14)	(58)
Investment income – related party	13	0	26	0
Investment income	524	534	1,163	1,040
Other income – related party		577		577
Other income	1			1
Income Before Provision for Income Taxes and Noncontrolling Interests	2,967	5,986	8,216	13,016
Provision for income taxes	(762)	(1,366)	(2,011)	(3,036)
Consolidated Net Income	2,205	4,620	6,205	9,980
Net Income Noncontrolling Interests	(241)	(861)	(1,106)	(2,115)
Net Income – Attributable to FONAR	$ 1,964	$ 3,759	$ 5,099	$ 7,865
Weighted Average Number of Shares Outstanding, Basic	6,686	6,437	6,696	6,448
Common Stockholders [Member]
Other income and (expenses)
Net Income Available to Common Stockholders	$ 1,840	$ 3,525	$ 4,775	$ 7,375
Earnings Per Share, Basic	$ 0.29	$ 0.55	$ 0.76	$ 1.14
Earnings Per Share, Diluted	$ 0.29	$ 0.54	$ 0.74	$ 1.12
Weighted Average Number of Shares Outstanding, Basic	6,303	6,437	6,313	6,448
Weighted Average Number of Shares Outstanding, Diluted	6,431	6,565	6,441	6,576
Class A Non Voting Preferred Stockholders [Member]
Other income and (expenses)
Net Income Available to Common Stockholders	$ 93	$ 175	$ 241	$ 365
Common Class C [Member]
Other income and (expenses)
Net Income Available to Common Stockholders	$ 31	$ 59	$ 83	$ 125
Earnings Per Share, Diluted	$ 0.08	$ 0.16	$ 0.22	$ 0.33
Weighted Average Number of Shares Outstanding, Basic	383	383	383	383
Weighted Average Number of Shares Outstanding, Diluted	383	383	383	383

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock, Common [Member]	Noncontrolling Interest [Member]	Total
Balance – June 30, 2023 at Jun. 30, 2023	$ 1	$ 182,613	$ (24,191)	$ (516)	$ (7,079)	$ 150,828
Beginning balance, shares at Jun. 30, 2023	6,451			11
Net income			7,865			7,865
Purchase of Treasury stock				$ (1,885)		(1,885)
Purchase of Treasury stock, shares				116
Cancellation of shares		(2,006)		$ 2,006
Cancellation of shares, shares	(123)			(123)
Distributions - Non controlling interests					(2,626)	(2,626)
Income - Non controlling interests					2,115	2,115
Balance – December 31, 2023 at Dec. 31, 2023	$ 1	180,607	(16,326)	$ (395)	(7,590)	156,297
Ending balance, shares at Dec. 31, 2023	6,328			4
Balance – June 30, 2023 at Sep. 30, 2023	$ 1	182,613	(20,085)	$ (1,230)	(7,226)	154,073
Beginning balance, shares at Sep. 30, 2023	6,451			55
Net income			3,759			3,759
Purchase of Treasury stock				$ (1,171)		(1,171)
Purchase of Treasury stock, shares				72
Cancellation of shares		(2,006)		$ 2,006
Cancellation of shares, shares	(123)			(123)
Distributions - Non controlling interests					(1,225)	(1,225)
Income - Non controlling interests					861	861
Balance – December 31, 2023 at Dec. 31, 2023	$ 1	180,607	(16,326)	$ (395)	(7,590)	156,297
Ending balance, shares at Dec. 31, 2023	6,328			4
Balance – June 30, 2023 at Jun. 30, 2024	$ 1	180,608	(13,624)	$ (1,017)	(9,180)	156,788
Beginning balance, shares at Jun. 30, 2024	6,328			45
Net income			5,099			5,099
Purchase of Treasury stock				$ (1,341)		(1,341)
Purchase of Treasury stock, shares				84
Cancellation of Treasury stock		(1,963)		$ 1,963
Sale - Non controlling interests		113			19	132
Distributions - Non controlling interests					(2,833)	(2,833)
Income - Non controlling interests					1,106	1,106
Balance – December 31, 2023 at Dec. 31, 2024	$ 1	178,758	(8,525)	$ (395)	(10,888)	158,951
Ending balance, shares at Dec. 31, 2024	6,203			4
Balance – June 30, 2023 at Sep. 30, 2024	$ 1	180,608	(10,489)	$ (1,432)	(9,861)	158,827
Beginning balance, shares at Sep. 30, 2024	6,328			69
Net income			1,964			1,964
Purchase of Treasury stock				$ (926)		(926)
Purchase of Treasury stock, shares				60
Cancellation of Treasury stock		(1,963)		$ 1,963
Cancellation of Treasury stock, shares	(125)			(125)
Sale - Non controlling interests		113			19	132
Distributions - Non controlling interests					(1,287)	(1,287)
Income - Non controlling interests					241	241
Balance – December 31, 2023 at Dec. 31, 2024	$ 1	$ 178,758	$ (8,525)	$ (395)	$ (10,888)	$ 158,951
Ending balance, shares at Dec. 31, 2024	6,203			4

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Cash Flows from Operating Activities:
Consolidated Net income	$ 6,205	$ 9,980
Adjustments to reconcile consolidated net income to net cash provided by operating activities:
Depreciation and amortization	2,298	2,415
Net change in operating right of use assets and lease liabilities	(63)	(119)
Provision for credit losses	1,279	355
Deferred tax expense	1,111	2,284
Gain on sale of equipment – related party		(577)
Changes in operating assets and liabilities, net:
Accounts, medical and management fee receivable(s)	(435)	(4,958)
Notes receivable		50
Notes receivable – related party	(26)
Inventories	(143)	(265)
Prepaid expenses and other current assets	(677)	217
Other assets	(11)	22
Accounts payable	(903)	(244)
Other current liabilities	(4,556)	(2,341)
Financing lease liabilities	(86)	(108)
Customer deposits	(87)	(3)
Other liabilities	(7)	(19)
Net cash provided by operating activities	3,899	6,689
Cash Flows from Investing Activities:
Purchases of property and equipment	(2,552)	(192)
Proceeds from short term investments	15
Cost of patents	(20)	(20)
Net cash used in investing activities	(2,557)	(212)
Cash Flows from Financing Activities:
Repayment of borrowings and capital lease obligations	(58)	(21)
Sale of noncontrolling interest	132
Purchase of treasury stock	(1,341)	(1,885)
Distributions to noncontrolling interests	(2,833)	(2,626)
Net cash used in financing activities	(4,100)	(4,532)
Net (Decrease) Increase in Cash and Cash Equivalents	(2,758)	1,945
Cash and Cash Equivalents - Beginning of Period	56,341	51,280
Cash and Cash Equivalents - End of Period	$ 53,583	$ 53,225

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ 1,964	$ 3,759	$ 5,099	$ 7,865

Insider Trading Arrangements

Insider Trading Arrangements	6 Months Ended
	Dec. 31, 2024
Trading Arrangements, by Individual [Table]
Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false

DESCRIPTION OF BUSINESS AND BAS

DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION	6 Months Ended
	Dec. 31, 2024
Description Of Business And Basis Of Presentation
DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION	NOTE 1 – DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Description of Business FONAR Corporation (the “Company” or “FONAR”) is a Delaware corporation, which was incorporated on July 17, 1978. FONAR is engaged in the research, development, production and marketing of medical scanning equipment, which uses principles of Magnetic Resonance Imaging (“MRI”) for the detection and diagnosis of human diseases. In addition to deriving revenues from the direct sale of MRI equipment, revenue is also generated from our installed-base of customers through our service and upgrade programs. FONAR, through its wholly-owned subsidiary Health Management Corporation of America (“HMCA”) provides comprehensive management services to diagnostic imaging facilities. The services provided by the Company include development, administration, leasing of office space, facilities and medical equipment, provision of supplies, staffing and supervision of non-medical personnel, legal services, accounting, billing and collection and the development and implementation of practice growth and marketing strategies. Effective July 1, 2015, the Company restructured the corporate organization of the management of diagnostic imaging centers segment of our business. The reorganization was structured to more completely integrate the operations of Health Management Corporation of America and Health Diagnostics Management (“HDM”). Imperial Management Services, LLC contributed all of its assets (which were utilized in the business of Health Management Corporation of America) to HDM and received a 24.2 % interest in HDM. Health Management Corporation of America retained a direct ownership interest of 45.8 % in HDM, and the original investors in HDM retained a 30.0 % ownership interest in the newly expanded HDM. As of June 30, 2024, the Company had a direct ownership interest of 70.8 % and the investors’ a 29.2 % ownership interest. During the quarter ended December 31, 2024, the Company sold non-controlling interests to a minority shareholder for $ 132 . Currently, the Company has a direct ownership interest of 70.63 % and the investors’ have a 29.37 % ownership interest. The entire management of diagnostic imaging centers business segment is now being conducted by HDM, operating under the name “Health Management Company of America”. Basis of Presentation These unaudited condensed consolidated financial statements for the period ended December 31, 2024 have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission pertaining to interim financial statements. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2024, from which the accompanying balance sheet at June 30, 2024 was derived. All intercompany balances and transactions have been eliminated in consolidation. In the opinion of management, all adjustments considered necessary for a fair presentation of the interim financial information have been included and are of a normal recurring nature. The preparation of the condensed consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the disclosure and reported amounts of assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation (Continued) The Company evaluates theses estimates and judgements on an ongoing basis. The Company bases estimates and judgements on historical experience and on various other factors that are believed to be reasonable under the circumstances. The results of operations for any interim period are not necessarily indicative of the results of operations for a full year. Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of FONAR Corporation, its majority and wholly-owned subsidiaries and partnerships (collectively, the “Company”). All significant intercompany accounts and transactions have been eliminated in consolidation. Revenue Recognition The Company’s revenues generally relate to net patient fees received from various payers and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services are satisfied. The Company’s performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than the Company’s standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. The Company’s patient fee revenue, net of contractual allowances and discounts for the three and six months ended December 31, 2024 and 2023 are summarized in the following table: Schedule of patient fee revenue - net For the Three Months Ended 2024 2023 Commercial Insurance/Managed Care $ 1,174 $ 1,243 Medicare/Medicaid 301 284 Workers’ Compensation/Personal Injury 4,683 4,907 Other 1,786 1,787 Patient Fee Revenue, net of contractual allowances and discounts $ 7,944 $ 8,221 Revenue Recognition (Continued) For the Six Months Ended 2024 2023 Commercial Insurance/ Managed Care $ 2,378 $ 2,416 Medicare/Medicaid 562 555 Workers’ Compensation/Personal Injury 9,382 10,044 Other 3,109 3,881 Patient Fee Revenue, net of contractual allowances and discounts $ 15,431 $ 16,896 Management and other fee receivable HMCA generates revenues from providing comprehensive management services, including development, administration, accounting, billing and collection services, together with office space, medical equipment, supplies and non-medical personnel to its clients. Revenues are in the form of fees which are earned under annual management contracts with HMCA clients. Management fee receivable is related to the management fees outstanding from the related and non-related professional corporations (“PCs”) under the management agreements. Earnings Per Share Basic earnings per share (“EPS”) is computed based upon the weighted average number of shares of common stock and stock equivalents outstanding, net of common stock. In accordance with ASC Topic 260-10, “Participating Securities and the Two-Class method”, the Company used the Two-Class method for calculating basic income per share and applied the converted method in calculating diluted income per share for the three and six months ended December 31, 2024 and 2023. Diluted EPS reflects the potential dilution from the exercise or conversion of all dilutive securities into common stock based on the average market price of common shares outstanding during the period. For the three and six months ended December 31, 2024 and 2023, diluted EPS for common shareholders includes 128 shares upon conversion of Class C Common. Schedule of earning per share Three months ended Three months ended Total Common Stock Class C Common Total Common Stock Class C Common Basic Numerator: $ 1,964 $ 1,840 $ 31 $ 3,759 $ 3,525 $ 59 Denominator: Weighted average shares outstanding 6,686 6,303 383 6,437 6,437 383 Basic income per common share $ 0.31 $ 0.29 $ 0.08 $ 0.58 $ 0.55 $ 0.16 Diluted Denominator: 6,303 383 6,437 383 Convertible Class C Stock 128 — 128 — Total Denominator for diluted earnings per share 6,431 383 6,565 383 Diluted income per common share $ 0.29 $ 0.08 $ 0.54 $ 0.16 Six months ended Six months ended Total Common Stock Class C Common Total Common Stock Class C Common Basic Numerator: $ 5,099 $ 4,775 $ 83 $ 7,865 $ 7,375 $ 125 Denominator: Weighted average shares outstanding 6,696 6,313 383 6,448 6,448 383 Basic income per common share $ 0.81 $ 0.76 $ 0.22 $ 1.22 $ 1.14 $ 0.33 Diluted Denominator: 6,313 383 6,448 383 Convertible Class C Stock 128 — 128 — Total Denominator for diluted earnings per share 6,441 383 6,576 383 Diluted income per common share $ 0.74 $ 0.22 $ 1.12 $ 0.33 Correction of immaterial errors In conjunction with preparing its interim financial statements for the three and six months ended December 31, 2024, the Company determined that its calculation of Right to Use Assets and Operating Lease Liabilities at the end of the past two annual periods and at September 30, 2024 and 2023 contained three immaterial errors. The Company evaluated the errors, both qualitatively and quantitatively, and determined that no prior interim or annual periods were materially misstated. The Company then evaluated whether the cumulative amount of the misstatement was material to its projected fiscal 2025 results of operations, and determined the cumulative amount was not material. Therefore, the Condensed Consolidated Financial Statements for the six and three months ended December 31, 2024 include an out-of-period correction of the following three items; a) a reclass of a software license of $ 1.3 million from Right to Use Asset/Liabilities to an intangible asset, b) a decrease to ROU of $ 1.7 million and an increase to Lease Liability of $ 1.1 million to correct the discounting of future lease payments and c) correct the accounting for 6 lease modifications.. The correction of these three errors resulted in an out of period charge to expenses of $ 116 to pre-tax income for the three and six months ended December 31, 2024. Recent Accounting Standards In December 2023, The Financial Accounting Standards Board (“FASB”) issued ASU 2023-09, “Income Taxes (Topic 740) Improvements to Income Tax Disclosures, which requires the annual financial statements to include consistent categories and great disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company’s annual reporting beginning after December 15, 2024, with early adoption permitted, and should be applied on a prospective basis, with a retrospective option. The Company is currently evaluating the effect that the adoption of ASU 2023-09 will have on its disclosures. In November 2023, FASB issued ASU 2023-07, “Segment Reporting (Topic 280)”, which is intended to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. The amendments require disclosure of significant segment expenses regularly provided to the chief operating decision maker (“CODM”) as well as other segment items, extended certain annual disclosures to interim periods, clarify the applicability to single reportable segment entities, permit more than one measure of profit or loss to be reported under certain conditions, and require disclosure of the title and position of the CODM. The effective date for public entities is for fiscal years beginning after December 15, 2023 and interim periods with fiscal years beginning after December 15, 2024. The Company is expected to adopt the new disclosures as required and are currently evaluating the impact on the related disclosures. Recent Accounting Standards FASB, the Emerging Issues Task Force and the SEC have issued certain other accounting standards, updates, and regulations as of December 31, 2024 that will become effective in subsequent periods; however, management does not believe that any of those updates would have significantly affected our financial accounting measures or disclosures had they been in effect during 2024 or 2023, and it does not believe that any of those standards will have a significant impact on our unaudited consolidated condensed financial statements at the time they become effective.

ACCOUNTS RECEIVABLE, MEDICAL RE

ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE	6 Months Ended
	Dec. 31, 2024
Receivables [Abstract]
ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE	NOTE 3 – ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE Receivables, net are comprised of the following at December 31, 2024, and June 30, 2024: Schedule of financing receivable noncurrent allowance for credit loss December 31, 2024 Gross Receivable Allowance for credit losses Net Accounts receivable $ 3,663 $ 273 $ 3,390 Accounts receivable - related party $ 60 $ — $ 60 Medical receivable $ 23,496 $ — $ 23,496 Management and other fees receivable $ 55,148 $ 12,663 $ 42,485 Management and other fees receivable from related medical practices (“PC’s”) $ 16,666 $ 6,989 $ 9,677 June 30, 2024 Gross Receivable Allowance for credit losses Net Accounts receivable $ 4,201 $ 166 $ 4,035 Medical receivable $ 23,992 $ — $ 23,992 Management and other fees receivable $ 54,324 $ 12,370 $ 41,954 Management and other fees receivable from related medical practices (“PC’s”) $ 15,975 $ 6,110 $ 9,865 The Company’s customers are concentrated in the healthcare industry. Accounts Receivable Credit risk with respect to the Company’s accounts receivable related to product sales and service and repair fees is limited due to the customer advances received prior to the commencement of work performed and the billing of amounts to customers as sub-assemblies are completed. Service and repair fees are billed on a monthly or quarterly basis and the Company does not continue providing these services if accounts receivable become past due. The Company has established a current expected credit loss (“CECL”) to address the risk that a portion of these fees will not be paid. The Company controls credit risk with respect to accounts receivable from service and repair fees through its credit evaluation process, credit limits, monitoring procedures and reasonably short collection terms. The Company performs ongoing credit authorizations before a product sales contract is entered into or service and repair fees are provided. Long Term-Accounts Receivable Long term-accounts receivable balances at December 31, 2024 and June 30, 2024 amounted to approximately $ 724 and $ 830 respectively. The Company will generate revenue from long-term, non-cancellable contracts to provide service and repair services. Future revenue to be recognized over the following four years as of December 31, 2024 is as follows: Schedule of future revenue 2026 $ 677 2027 242 2028 87 2029 44 Total $ 1,050 Medical Receivables Medical receivables are due under fee-for-service contracts from third party payors, such as hospitals, government sponsored healthcare programs, patient’s legal counsel and directly from patients. Substantially all the revenue relates to patients residing in Florida. Medical receivables are recorded at net realizable value based on the estimated amounts the Company expects to receive from patients and third-party payors. The medical receivable is reduced by contractual adjustments based on the historical experience with each payor class at each location. Management and Other Fees Receivable Management fees receivable is related to management fees outstanding from the related and non related PCs under management agreements. The Company has established a CECL to address the risk that a portion of the contractually obligated management fees receivable from the PCs may not be paid. The PC’s may be limited in their ability to pay the full management fee receivable if they do not collect sufficient expected fees from third-party payers and patients. The Company’s management fees are collateralized, individually and collectively, by the assets of the PCs. The CECL is determined based on the difference between the management fee receivable and the current amount of outstanding fees estimated to be collected by the PCs. Management and Other Fees Receivable (Continued) The Company’s considerations into the estimate of the PC’s fee collection is based on a combination of factors. As each management agreement specifies the Company’s ultimate collateral for unpaid management fees are the patient fee receivables owned by each PC, the Company considers the historical loss rates to pools of receivables with similar risks characteristics, aging of the patient fee receivables, and the financial condition of each PC. In addition, the Company subjectively adjusts its estimated expected credit losses for current and forward-looking economic conditions which would include trends seen within the industry and newly enacted regulation. The Company also incorporates qualitative factors, such as changes in the nature and volume of receivables, regulatory changes, and other relevant factors. Specifically, insurance carriers covering automobile no-fault and workers compensation claims incur longer payment cycles and rigorous informational requirements and certain other disallowed claims. Approximately 58.2 % and 54.4 % of the Company’s owned PCs’ net revenues were derived from no-fault and personal injury protection claims for the three months ending December 31, 2024 and 2023, respectively. In addition, 59.3 % and 57.5 % of the Company’s owned PC’s net revenues were derived from no-fault and personal injury protection claims for the six months ending December 31, 2024 and 2023, respectively. Also approximately 72.5 % and 71.7 % of the Company’s managed PCs’ net revenues were derived from no-fault and personal injury protection claims for the three months ending December 31, 2024 and 2023, respectively. In addition 72.2 % and 71.8 % of the Company’s net revenues were derived from no-fault and personal injury protection claims for the six months ending December 31, 2024 and 2023, respectively. The Company combines an objective and subjective loss-rate methodology to estimate expected credit losses based on the collateral owned by each PC. This involves objectively using historical loss rates to pools of receivables with similar risk characteristics (i.e. various insurance payors) and then subjectively adjusting for current and forward-looking economic conditions which would include trends seen within the industry and newly enacted regulation. The Company also incorporates qualitative factors, such as changes in the nature and volume of the receivables, regulatory changes, and other relevant factors. Additional Company managed entities also operate under a guaranty agreement, pursuant to which management fees are payable to the Company. Net revenues from management and other fees charged to the related PCs accounted for approximately 12.0 % and 11.8 % of the consolidated net revenues for the three months ended December 31, 2024 and 2023, respectively. Net revenues from management and other fees charges to the related PCs accounted for approximately 12.0 % and 11.7 % of the consolidated net revenues for the six months ended December 31, 2024 and 2023, respectively.

OPERATING AND FINANCING LEASES

OPERATING AND FINANCING LEASES	6 Months Ended
	Dec. 31, 2024
Operating And Financing Leases
OPERATING AND FINANCING LEASES	NOTE 4 – OPERATING AND FINANCING LEASES The Company accounts for its various operating leases in accordance with Accounting Standards Codification (ASC) 842 – “Leases”, as updated by ASU 2016-02. At the inception of a lease, the Company recognizes right-of-use lease assets and related lease liabilities measured at present value of future lease payments on its balance sheet. Lease expense is recognized on a straight-line basis over the term of the lease. The Company most common initial term varies in length from 2 to 19 years. Including renewal options negotiated with the landlord, we have a total span of 2 to 16 years at the facilities we lease. The Company reviewed its contracts with vendors and customers, determining that its right-to-use lease assets consisted of only office space operating leases. In determining the right-to-use lease assets and liabilities, the Company did recognize lease extension options which the Company feels would be reasonably exercised. Our incremental borrowing rate (“IBR”) used to discount the stream of operating lease payments is closely related to the interest rates available to the Company. A reconciliation of operating and financing lease payments undiscounted cash flows to lease liabilities recognized as of December 31, 2024 is as follows: Schedule of lessee operating leases liability maturity Twelve Months Ending Operating Lease Financing Lease Payments 2025 $ 5,584 $ 244 2026 5,388 244 2027 5,371 61 2028 5,019 — 2029 4,876 — Thereafter 26,841 — Present value discount (14,893 ) (15 ) Total lease liability $ 38,186 $ 534 Weighted Average Remaining Lease Term Schedule of weighted average remaining lease term Operating leases - years 10.6 Finance lease - years 2.1 Weighted Average Discount Rate Operating leases 6.5 % Finance lease 3.6 % The components of lease expense were as follows: Components of lease expense For the six months ended Dec.31, 2024 2023 Operating lease cost $ 3,190 $ 2,865 Finance lease cost: Depreciation of leased equipment $ 100 $ 100 Interest on lease liabilities 5 14 Total finance lease cost $ 105 $ 114 Supplemental cash flow information related to leases was as follows: Supplemental cash flow information related to leases For the six months ended Dec. 31, Cash paid for amounts included in the measurement of lease liabilities: 2024 2023 Operating cash flows from operating leases $ 2,541 $ 3,164 Financing cash flows from financing leases $ 122 $ 122 Right-of-use and equipment assets obtained in exchange for lease obligations: Operating leases $ 359 $ 1,212

INVENTORIES

INVENTORIES	6 Months Ended
	Dec. 31, 2024
Inventory Disclosure [Abstract]
INVENTORIES	NOTE 5 - INVENTORIES Inventories included in the accompanying condensed consolidated balance sheets consist of the following: Schedule of inventories December 31, June 30, Purchased parts, components and supplies $ 2,583 $ 2,524 Work-in-process 275 191 Total Inventories $ 2,858 $ 2,715

OTHER INTANGIBLE ASSETS

OTHER INTANGIBLE ASSETS	6 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
OTHER INTANGIBLE ASSETS	NOTE 6 – OTHER INTANGIBLE ASSETS Other intangible assets, net of accumulated amortization, in the accompanying condensed consolidated balance sheets consist of the following: Schedule of other intangible assets Weighted average useful lives Gross carrying amount – December 31, 2024 Accumulated amortization – December 31, 2024 Net carrying amount – December 31, 2024 Capitalized software development costs 5 years $ 7,005 $ (7,005 ) $ — Software License 3 years 1,260 (567 ) 693 Patents and copy rights 15 years 5,280 (4,180 ) 1,100 Non-compete 7 years 4,150 (4,150 ) — Customer relationships 20 years 3,900 (2,286 ) 1,614 Total $ 21,595 $ (18,188 ) $ 3,407 Weighted average useful lives Gross carrying amount – June 30, 2024 Accumulated amortization Net carrying amount Capitalized software development costs 5 years $ 7,005 $ (7,005 ) $ — Patents and copy rights 15 years 5,260 (4,104 ) 1,156 Non-compete 7 years 4,150 (4,150 ) — Customer relationships 20 years 3,900 (2,186 ) 1,714 Total $ 20,315 $ (17,445 ) $ 2,870 Amortization of patents and copyrights for the three months ended December 31, 2024 and 2023 amounted to $ 37 and $ 43 , respectively. Amortization of customer relationships for the three months ended December 31, 2024 and 2023 amounted to $ 50 and $ 50 , respectively. Amortization of patents and copyrights for the six months ended December 31, 2024 and 2023 amounted to $ 76 and $ 86 , respectively. Amortization of customer relationships for the six months ended December 31, 2024 and 2023 amounted to $ 100 and $ 100 , respectively. Amortization expense for reach of the next five years and thereafter as of December 31, 2024 are as follows: 2025 723 2026 650 2027 321 2028 317 2029 314 Thereafter 1082 Total $ 3,407

OTHER CURRENT LIABILITIES

OTHER CURRENT LIABILITIES	6 Months Ended
	Dec. 31, 2024
Payables and Accruals [Abstract]
OTHER CURRENT LIABILITIES	NOTE 7 – OTHER CURRENT LIABILITIES Other current liabilities in the accompanying condensed consolidated balance sheets consist of the following: Schedule of other current liabilities December 31, June 30, Accrued salaries, commissions and payroll taxes $ 1,541 $ 4,678 Sales tax payable 183 197 Federal and state income taxes payable — 1,461 Self-funded health insurance reserve 168 121 Software Licenses 252 — Other general and administrative expenses 1,768 1,484 Other Current Liabilities $ 3,912 $ 7,941

SEGMENT AND RELATED INFORMATION

SEGMENT AND RELATED INFORMATION	6 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
SEGMENT AND RELATED INFORMATION	NOTE 8 - SEGMENT AND RELATED INFORMATION The Company operates in two industry segments - manufacturing and the servicing of medical equipment and management of diagnostic imaging centers. The accounting policies of the segments are the same as those described in the summary of significant accounting policies as disclosed in the Company’s 10-K as of June 30, 2024. All inter segment sales are market-based. The Company evaluates performance based on income or loss from operations. Summarized financial information concerning the Company’s reportable segments is shown in the following table: Schedule of summarized segment financial information Manufacturing and Service of MRI Equipment Management of Diagnostic Imaging Centers Totals For the three months ended December 31, 2024 Net revenues from external customers $ 1,829 $ 23,121 $ 24,950 Inter-segment net revenues $ 294 $ — $ 294 (Loss) Income from operations $ (1,291 ) $ 3,726 $ 2,435 Depreciation and amortization $ 54 $ 1,181 $ 1,235 Capital expenditures $ 23 $ 731 $ 754 For the three months ended December 31, 2023 Net revenues from external customers $ 1,861 $ 23,525 $ 25,386 Inter-segment net revenues $ 254 $ — $ 254 (Loss) Income from operations $ (993 ) $ 5,878 $ 4,885 Depreciation and amortization $ 60 $ 1,160 $ 1,220 Capital expenditures $ 4 $ 129 $ 133 Manufacturing and Service of MRI Equipment Management of Diagnostic Imaging Centers Totals For the six months ended December 31, 2024 Net revenues from external customers $ 3,986 $ 45,924 $ 49,910 Inter-segment net revenues $ 583 $ — $ 583 (Loss) Income from operations $ (2,335 ) $ 9,376 $ 7,041 Depreciation and amortization $ 103 $ 2,195 $ 2,298 Capital expenditures $ 95 $ 2,477 $ 2,572 Manufacturing and Service of MRI Equipment Management of Diagnostic Imaging Centers Totals For the six months ended December 31, 2023 Net revenues from external customers $ 3,917 $ 47,307 $ 51,224 Inter-segment net revenues $ 508 $ — $ 508 (Loss) Income from operations $ (1,731 ) $ 13,187 $ 11,456 Depreciation and amortization $ 121 $ 2,294 $ 2,415 Capital expenditures $ 20 $ 192 $ 212

SUPPLEMENTAL CASH FLOW INFORMAT

SUPPLEMENTAL CASH FLOW INFORMATION	6 Months Ended
	Dec. 31, 2024
Supplemental Cash Flow Elements [Abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	NOTE 9 – SUPPLEMENTAL CASH FLOW INFORMATION During the six months ended December 31, 2024 and December 31, 2023, the Company paid $ 14 and $ 58 for interest, respectively. During the six months ended December 31, 2024 and December 31, 2023, the Company paid $ 2,473 and $ 150 for income taxes, respectively. During the six months ended December 31, 2024 and December 31, 2023, the Company obtained right-of-use and equipment assets in exchange for lease obligations of $ 359 and $ 1,212 , respectively. During the three months ended December 31, 2024, the Company sold a 0.197 % interest in HDM to an employee. The interest was sold for $ 132,000 in a noncash transaction.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 10 – COMMITMENTS AND CONTINGENCIES Litigation The Company is subject to legal proceedings and claims arising from the ordinary course of its business, including personal injury, customer contract and employment claims. In the opinion of management, the aggregate liability, if any, with respect to such actions, will not have a material adverse effect on the consolidated financial position or results of operations of the Company. In the ordinary course of its business, the Company is a party to various lawsuits arising from the operations at the MRI sites and other insurance related matters, which are generally handled by the Company’s insurance carriers. Management believes, based in part on the advice counsel, that the ultimate resolution of these matters will not have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows. There were no material changes in litigation from that reported in our Form 10-K for the fiscal year ended June 30, 2024. Other Matters On September 13, 2022, the Company adopted a stock repurchase plan. The plan has no expiration date and cannot determine the number of shares which will be repurchased. On September 26, 2022, the Board of Directors has approved up to $ 9,000 to be repurchased under the plan which will be purchased on the publicly traded open market at prevailing prices. During the six months ended December 31, 2024 and 2023, the Company repurchased 84 and 116 shares at a cost of $ 1,342 and $ 1,885 , respectively. The Company cancelled 125 shares and 123 shares at a cost of $ 1,963 and $ 2,005 for the six months ended December 31, 2024 and 2023, respectively. As of December 31, 2024 the remaining balance under the repurchase plan was $ 3,392 . The Company maintains a self-funded health insurance program with a stop-loss umbrella policy with a third-party insurer to limit the maximum potential liability for individual claims to $ 150 per person and for a maximum potential claim liability based on member enrollment. With respect to this program, the Company considers historical and projected medical utilization data when estimating its health insurance program liability and related expense. As of December 31, 2024 and June 30, 2024, the Company had approximately $ 168 and $ 86 , respectively, in reserve for its self-funded health insurance programs. The reserves are included in “Other current liabilities” in the condensed consolidated balance sheets. The Company regularly analyzes its reserves for incurred but not reported claims, and for reported but not paid claims related to its reinsurance and self-funded insurance programs. The Company believes its reserves are adequate. However, significant judgment is involved in assessing these reserves such as assessing historical paid claims, average lags between the claims’ incurred date, reported dates and paid dates, and the frequency and severity of claims. There may be differences between actual settlement amounts and recorded reserves and any resulting adjustments are included in expense once a probable amount is known. There were no significant adjustments recorded in the periods covered by this report.

INCOME TAXES

INCOME TAXES	6 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 11 - INCOME TAXES In accordance with ASC 740-270, “Income Taxes – Interim Reporting”, the Company is required at the end of each interim period to determine the best estimate of its annual effective tax rate and apply that rate to year-to-date ordinary income or loss. The resulting tax expense (or benefit) is adjusted for the tax effect of specific events, if any, required to be discretely recognized in the interim period as they occur. For the six months ended December 31, 2024 and 2023, the Company recorded income tax expense of $ 2,011 in 2024 as compared to $ 3,036 in 2023. For the three months ended December 31, 2024 and 2023, the Company recorded income tax expense of $ 762 and $ 1,366 , respectively. The six month and three month 2024 provision is comprised of a current income tax component of $ 900 and a deferred income tax component of $ 1,111 and a current income tax component of $ 517 and a deferred income tax component of $ 245 , respectively. Obligations for any liability associated with the current income tax provision has been reduced, primarily resulting from the benefits and utilization of net operating loss carryforwards. ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a corporate tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the benefit recognized and measured pursuant to the interpretation are referred to as unrecognized benefits. A liability is recognized (or amount of net operating loss carryforward or amount of tax refundable is reduced) for an unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC Topic 740. The Company believes there are no uncertain tax positions in prior year tax filings and therefore it has not recorded a liability for unrecognized tax benefits. The Company recorded a deferred tax asset of $ 6,113 and a deferred tax liability of $ 371 as of December 31, 2024, primarily relating to allowance for credit losses and tax credits. The Company files corporate income tax returns in the United States (federal) and in various state and local jurisdictions. In most instances, the Company is no longer subject to federal, state and local income tax examinations by tax authorities for years prior to 2020. Future ownership changes as determined under Section 382 of the Internal Revenue Code could further limit the utilization of net operating loss carryforwards. As of December 31, 2024, no such changes in ownership have occurred. The Inflation Reduction Act (“IRA”) was enacted on August 16, 2022. The IRA includes provisions imposing a 1 % excise tax on share repurchases that occur after December 31, 2022 and introduces a 15 % corporate alternative minimum tax (“CAMT”) on adjusted financial statement of income. The CAMT will be effective for tax years beginning after December 31, 2022. Currently, the IRA did not have a material impact to the Company’s financial statements.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Dec. 31, 2024
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 12 – RELATED PARTY TRANSACTIONS Tallahassee Magnetic Resonance Imaging, Inc. Stand Up MRI of Boca Raton, PA and Stand Up MRI & Diagnostic Center, Inc. (all related medical practices) entered into a guaranty agreement, pursuant to which they cross guaranteed all management fees which are payable to the Company, which have arisen under each individual management agreement. During the six months ended December 31, 2024 and 2023, the net revenues received by the Company was $ 5,975 . Bensonhurst MRI Limited Partnership (“Bensonhurst”), in which the CEO and President of the Company holds an interest, is party to an agreement with the Company for the service and maintenance of its Upright MRI Scanner for a price of $ 110,000 per annum. On February 1, 2024, Bensonhurst entered into a second contract with the Company for the service and maintenance of a High-Field MRI Scanner for a price of $ 70,000 per annum. For the six months ended December 31, 2024 and 2023 the Company recorded service and repair fees of $ 90 and $ 55 , respectively from Bensonhurst. Also during the three months ended December 31, 2024 and 2023 the Company recorded service and repair fees of $ 45 and $ 28 , respectively. Radian Healthcare Management, LLC (“Radian”), which is owned by the son-in-law of the CEO and President of the Company provided the Company with personnel recruitment of new employees at a fee of approximately $ 68 and $ 0 for the six months ended December 31, 2024 and 2023, respectively. On December 31, 2023, the Company entered into an agreement with Magnetic Resonance Management, LLC (“MRM”) for the sale of a MRI scanner. MRM is owned by the CEO and President of the Company. The sales price of the equipment was $ 577 which is payable based upon a promissory note dated December 1, 2023. The note bears interest at a rate of 9 % and is payable in full at the maturity of the note in December 2028. During the six months ending December 31, 2024 the Company recorded $ 26 in investment income on this promissory note. Also during the three months ending December 31, 2024, the Company recorded $ 13 in investment income on this promissory note. The MRI scanner had zero basis, which resulted in a gain of $ 577 , which was recorded during the year ended June 30, 2024. The Company has the option but not the obligation to re-take possession of the scanner in lieu of payment upon maturity of the note.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Dec. 31, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 13 – SUBSEQUENT EVENTS The Company has evaluated events that occurred subsequent to December 31, 2024 and through the date the condensed consolidated financial statements were issued. In the subsequent period up to the date of filing, the Company repurchased 7 shares of common stock at a cost of $ 108 which was authorized under the stock repurchase plan adopted in September 2022.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation (Continued) The Company evaluates theses estimates and judgements on an ongoing basis. The Company bases estimates and judgements on historical experience and on various other factors that are believed to be reasonable under the circumstances. The results of operations for any interim period are not necessarily indicative of the results of operations for a full year.
Principles of Consolidation	Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of FONAR Corporation, its majority and wholly-owned subsidiaries and partnerships (collectively, the “Company”). All significant intercompany accounts and transactions have been eliminated in consolidation.
Revenue Recognition	Revenue Recognition The Company’s revenues generally relate to net patient fees received from various payers and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services are satisfied. The Company’s performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than the Company’s standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. The Company’s patient fee revenue, net of contractual allowances and discounts for the three and six months ended December 31, 2024 and 2023 are summarized in the following table: Schedule of patient fee revenue - net For the Three Months Ended 2024 2023 Commercial Insurance/Managed Care $ 1,174 $ 1,243 Medicare/Medicaid 301 284 Workers’ Compensation/Personal Injury 4,683 4,907 Other 1,786 1,787 Patient Fee Revenue, net of contractual allowances and discounts $ 7,944 $ 8,221 Revenue Recognition (Continued) For the Six Months Ended 2024 2023 Commercial Insurance/ Managed Care $ 2,378 $ 2,416 Medicare/Medicaid 562 555 Workers’ Compensation/Personal Injury 9,382 10,044 Other 3,109 3,881 Patient Fee Revenue, net of contractual allowances and discounts $ 15,431 $ 16,896
Management and other fee receivable	Management and other fee receivable HMCA generates revenues from providing comprehensive management services, including development, administration, accounting, billing and collection services, together with office space, medical equipment, supplies and non-medical personnel to its clients. Revenues are in the form of fees which are earned under annual management contracts with HMCA clients. Management fee receivable is related to the management fees outstanding from the related and non-related professional corporations (“PCs”) under the management agreements.
Earnings Per Share	Earnings Per Share Basic earnings per share (“EPS”) is computed based upon the weighted average number of shares of common stock and stock equivalents outstanding, net of common stock. In accordance with ASC Topic 260-10, “Participating Securities and the Two-Class method”, the Company used the Two-Class method for calculating basic income per share and applied the converted method in calculating diluted income per share for the three and six months ended December 31, 2024 and 2023. Diluted EPS reflects the potential dilution from the exercise or conversion of all dilutive securities into common stock based on the average market price of common shares outstanding during the period. For the three and six months ended December 31, 2024 and 2023, diluted EPS for common shareholders includes 128 shares upon conversion of Class C Common. Schedule of earning per share Three months ended Three months ended Total Common Stock Class C Common Total Common Stock Class C Common Basic Numerator: $ 1,964 $ 1,840 $ 31 $ 3,759 $ 3,525 $ 59 Denominator: Weighted average shares outstanding 6,686 6,303 383 6,437 6,437 383 Basic income per common share $ 0.31 $ 0.29 $ 0.08 $ 0.58 $ 0.55 $ 0.16 Diluted Denominator: 6,303 383 6,437 383 Convertible Class C Stock 128 — 128 — Total Denominator for diluted earnings per share 6,431 383 6,565 383 Diluted income per common share $ 0.29 $ 0.08 $ 0.54 $ 0.16 Six months ended Six months ended Total Common Stock Class C Common Total Common Stock Class C Common Basic Numerator: $ 5,099 $ 4,775 $ 83 $ 7,865 $ 7,375 $ 125 Denominator: Weighted average shares outstanding 6,696 6,313 383 6,448 6,448 383 Basic income per common share $ 0.81 $ 0.76 $ 0.22 $ 1.22 $ 1.14 $ 0.33 Diluted Denominator: 6,313 383 6,448 383 Convertible Class C Stock 128 — 128 — Total Denominator for diluted earnings per share 6,441 383 6,576 383 Diluted income per common share $ 0.74 $ 0.22 $ 1.12 $ 0.33
Correction of immaterial errors	Correction of immaterial errors In conjunction with preparing its interim financial statements for the three and six months ended December 31, 2024, the Company determined that its calculation of Right to Use Assets and Operating Lease Liabilities at the end of the past two annual periods and at September 30, 2024 and 2023 contained three immaterial errors. The Company evaluated the errors, both qualitatively and quantitatively, and determined that no prior interim or annual periods were materially misstated. The Company then evaluated whether the cumulative amount of the misstatement was material to its projected fiscal 2025 results of operations, and determined the cumulative amount was not material. Therefore, the Condensed Consolidated Financial Statements for the six and three months ended December 31, 2024 include an out-of-period correction of the following three items; a) a reclass of a software license of $ 1.3 million from Right to Use Asset/Liabilities to an intangible asset, b) a decrease to ROU of $ 1.7 million and an increase to Lease Liability of $ 1.1 million to correct the discounting of future lease payments and c) correct the accounting for 6 lease modifications.. The correction of these three errors resulted in an out of period charge to expenses of $ 116 to pre-tax income for the three and six months ended December 31, 2024.
Recent Accounting Standards	Recent Accounting Standards In December 2023, The Financial Accounting Standards Board (“FASB”) issued ASU 2023-09, “Income Taxes (Topic 740) Improvements to Income Tax Disclosures, which requires the annual financial statements to include consistent categories and great disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company’s annual reporting beginning after December 15, 2024, with early adoption permitted, and should be applied on a prospective basis, with a retrospective option. The Company is currently evaluating the effect that the adoption of ASU 2023-09 will have on its disclosures. In November 2023, FASB issued ASU 2023-07, “Segment Reporting (Topic 280)”, which is intended to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. The amendments require disclosure of significant segment expenses regularly provided to the chief operating decision maker (“CODM”) as well as other segment items, extended certain annual disclosures to interim periods, clarify the applicability to single reportable segment entities, permit more than one measure of profit or loss to be reported under certain conditions, and require disclosure of the title and position of the CODM. The effective date for public entities is for fiscal years beginning after December 15, 2023 and interim periods with fiscal years beginning after December 15, 2024. The Company is expected to adopt the new disclosures as required and are currently evaluating the impact on the related disclosures. Recent Accounting Standards FASB, the Emerging Issues Task Force and the SEC have issued certain other accounting standards, updates, and regulations as of December 31, 2024 that will become effective in subsequent periods; however, management does not believe that any of those updates would have significantly affected our financial accounting measures or disclosures had they been in effect during 2024 or 2023, and it does not believe that any of those standards will have a significant impact on our unaudited consolidated condensed financial statements at the time they become effective.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Schedule of patient fee revenue - net	Schedule of patient fee revenue - net For the Three Months Ended 2024 2023 Commercial Insurance/Managed Care $ 1,174 $ 1,243 Medicare/Medicaid 301 284 Workers’ Compensation/Personal Injury 4,683 4,907 Other 1,786 1,787 Patient Fee Revenue, net of contractual allowances and discounts $ 7,944 $ 8,221 Revenue Recognition (Continued) For the Six Months Ended 2024 2023 Commercial Insurance/ Managed Care $ 2,378 $ 2,416 Medicare/Medicaid 562 555 Workers’ Compensation/Personal Injury 9,382 10,044 Other 3,109 3,881 Patient Fee Revenue, net of contractual allowances and discounts $ 15,431 $ 16,896
Schedule of earning per share	Schedule of earning per share Three months ended Three months ended Total Common Stock Class C Common Total Common Stock Class C Common Basic Numerator: $ 1,964 $ 1,840 $ 31 $ 3,759 $ 3,525 $ 59 Denominator: Weighted average shares outstanding 6,686 6,303 383 6,437 6,437 383 Basic income per common share $ 0.31 $ 0.29 $ 0.08 $ 0.58 $ 0.55 $ 0.16 Diluted Denominator: 6,303 383 6,437 383 Convertible Class C Stock 128 — 128 — Total Denominator for diluted earnings per share 6,431 383 6,565 383 Diluted income per common share $ 0.29 $ 0.08 $ 0.54 $ 0.16 Six months ended Six months ended Total Common Stock Class C Common Total Common Stock Class C Common Basic Numerator: $ 5,099 $ 4,775 $ 83 $ 7,865 $ 7,375 $ 125 Denominator: Weighted average shares outstanding 6,696 6,313 383 6,448 6,448 383 Basic income per common share $ 0.81 $ 0.76 $ 0.22 $ 1.22 $ 1.14 $ 0.33 Diluted Denominator: 6,313 383 6,448 383 Convertible Class C Stock 128 — 128 — Total Denominator for diluted earnings per share 6,441 383 6,576 383 Diluted income per common share $ 0.74 $ 0.22 $ 1.12 $ 0.33

ACCOUNTS RECEIVABLE, MEDICAL _2

ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Tables)	6 Months Ended
	Dec. 31, 2024
Receivables [Abstract]
Schedule of financing receivable noncurrent allowance for credit loss	Schedule of financing receivable noncurrent allowance for credit loss December 31, 2024 Gross Receivable Allowance for credit losses Net Accounts receivable $ 3,663 $ 273 $ 3,390 Accounts receivable - related party $ 60 $ — $ 60 Medical receivable $ 23,496 $ — $ 23,496 Management and other fees receivable $ 55,148 $ 12,663 $ 42,485 Management and other fees receivable from related medical practices (“PC’s”) $ 16,666 $ 6,989 $ 9,677 June 30, 2024 Gross Receivable Allowance for credit losses Net Accounts receivable $ 4,201 $ 166 $ 4,035 Medical receivable $ 23,992 $ — $ 23,992 Management and other fees receivable $ 54,324 $ 12,370 $ 41,954 Management and other fees receivable from related medical practices (“PC’s”) $ 15,975 $ 6,110 $ 9,865
Schedule of future revenue	Schedule of future revenue 2026 $ 677 2027 242 2028 87 2029 44 Total $ 1,050

OPERATING AND FINANCING LEASES

OPERATING AND FINANCING LEASES (Tables)	6 Months Ended
	Dec. 31, 2024
Operating And Financing Leases
Schedule of lessee operating leases liability maturity	Schedule of lessee operating leases liability maturity Twelve Months Ending Operating Lease Financing Lease Payments 2025 $ 5,584 $ 244 2026 5,388 244 2027 5,371 61 2028 5,019 — 2029 4,876 — Thereafter 26,841 — Present value discount (14,893 ) (15 ) Total lease liability $ 38,186 $ 534
Schedule of weighted average remaining lease term	Schedule of weighted average remaining lease term Operating leases - years 10.6 Finance lease - years 2.1 Weighted Average Discount Rate Operating leases 6.5 % Finance lease 3.6 %
Components of lease expense	Components of lease expense For the six months ended Dec.31, 2024 2023 Operating lease cost $ 3,190 $ 2,865 Finance lease cost: Depreciation of leased equipment $ 100 $ 100 Interest on lease liabilities 5 14 Total finance lease cost $ 105 $ 114
Supplemental cash flow information related to leases	Supplemental cash flow information related to leases For the six months ended Dec. 31, Cash paid for amounts included in the measurement of lease liabilities: 2024 2023 Operating cash flows from operating leases $ 2,541 $ 3,164 Financing cash flows from financing leases $ 122 $ 122 Right-of-use and equipment assets obtained in exchange for lease obligations: Operating leases $ 359 $ 1,212

INVENTORIES (Tables)

INVENTORIES (Tables)	6 Months Ended
	Dec. 31, 2024
Inventory Disclosure [Abstract]
Schedule of inventories	Schedule of inventories December 31, June 30, Purchased parts, components and supplies $ 2,583 $ 2,524 Work-in-process 275 191 Total Inventories $ 2,858 $ 2,715

OTHER INTANGIBLE ASSETS (Tables

OTHER INTANGIBLE ASSETS (Tables)	6 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of other intangible assets	Schedule of other intangible assets Weighted average useful lives Gross carrying amount – December 31, 2024 Accumulated amortization – December 31, 2024 Net carrying amount – December 31, 2024 Capitalized software development costs 5 years $ 7,005 $ (7,005 ) $ — Software License 3 years 1,260 (567 ) 693 Patents and copy rights 15 years 5,280 (4,180 ) 1,100 Non-compete 7 years 4,150 (4,150 ) — Customer relationships 20 years 3,900 (2,286 ) 1,614 Total $ 21,595 $ (18,188 ) $ 3,407 Weighted average useful lives Gross carrying amount – June 30, 2024 Accumulated amortization Net carrying amount Capitalized software development costs 5 years $ 7,005 $ (7,005 ) $ — Patents and copy rights 15 years 5,260 (4,104 ) 1,156 Non-compete 7 years 4,150 (4,150 ) — Customer relationships 20 years 3,900 (2,186 ) 1,714 Total $ 20,315 $ (17,445 ) $ 2,870
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	2025 723 2026 650 2027 321 2028 317 2029 314 Thereafter 1082 Total $ 3,407

OTHER CURRENT LIABILITIES (Tabl

OTHER CURRENT LIABILITIES (Tables)	6 Months Ended
	Dec. 31, 2024
Payables and Accruals [Abstract]
Schedule of other current liabilities	Schedule of other current liabilities December 31, June 30, Accrued salaries, commissions and payroll taxes $ 1,541 $ 4,678 Sales tax payable 183 197 Federal and state income taxes payable — 1,461 Self-funded health insurance reserve 168 121 Software Licenses 252 — Other general and administrative expenses 1,768 1,484 Other Current Liabilities $ 3,912 $ 7,941

SEGMENT AND RELATED INFORMATI_2

SEGMENT AND RELATED INFORMATION (Tables)	6 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Schedule of summarized segment financial information	Schedule of summarized segment financial information Manufacturing and Service of MRI Equipment Management of Diagnostic Imaging Centers Totals For the three months ended December 31, 2024 Net revenues from external customers $ 1,829 $ 23,121 $ 24,950 Inter-segment net revenues $ 294 $ — $ 294 (Loss) Income from operations $ (1,291 ) $ 3,726 $ 2,435 Depreciation and amortization $ 54 $ 1,181 $ 1,235 Capital expenditures $ 23 $ 731 $ 754 For the three months ended December 31, 2023 Net revenues from external customers $ 1,861 $ 23,525 $ 25,386 Inter-segment net revenues $ 254 $ — $ 254 (Loss) Income from operations $ (993 ) $ 5,878 $ 4,885 Depreciation and amortization $ 60 $ 1,160 $ 1,220 Capital expenditures $ 4 $ 129 $ 133 Manufacturing and Service of MRI Equipment Management of Diagnostic Imaging Centers Totals For the six months ended December 31, 2024 Net revenues from external customers $ 3,986 $ 45,924 $ 49,910 Inter-segment net revenues $ 583 $ — $ 583 (Loss) Income from operations $ (2,335 ) $ 9,376 $ 7,041 Depreciation and amortization $ 103 $ 2,195 $ 2,298 Capital expenditures $ 95 $ 2,477 $ 2,572 Manufacturing and Service of MRI Equipment Management of Diagnostic Imaging Centers Totals For the six months ended December 31, 2023 Net revenues from external customers $ 3,917 $ 47,307 $ 51,224 Inter-segment net revenues $ 508 $ — $ 508 (Loss) Income from operations $ (1,731 ) $ 13,187 $ 11,456 Depreciation and amortization $ 121 $ 2,294 $ 2,415 Capital expenditures $ 20 $ 192 $ 212

DESCRIPTION OF BUSINESS AND B_2

DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative) - Nonconsolidated Investees, Other [Member] - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2024	Jun. 30, 2024	Jul. 01, 2015
Investment Owned, Net Assets, Percentage			24.20%
Equity Method Investment, Ownership Percentage	70.63%	70.80%	45.80%
Proceeds from (Payments to) Noncontrolling Interests	$ 132
Noncontrolling Interest [Member]
Equity Method Investment, Ownership Percentage	29.37%	29.20%	30%

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Fee Revenue Recognition - (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Disaggregation of Revenue [Line Items]
Patient Fee Revenue, net of contractual allowances and discounts	$ 7,944	$ 8,221	$ 15,431	$ 16,896
Commercial Insurance Managed Care [Member]
Disaggregation of Revenue [Line Items]
Patient Fee Revenue, net of contractual allowances and discounts	1,174	1,243	2,378	2,416
Medicare Medicaid [Member]
Disaggregation of Revenue [Line Items]
Patient Fee Revenue, net of contractual allowances and discounts	301	284	562	555
Workers Compensation Personal Injury [Member]
Disaggregation of Revenue [Line Items]
Patient Fee Revenue, net of contractual allowances and discounts	4,683	4,907	9,382	10,044
Other Revenue Source [Member]
Disaggregation of Revenue [Line Items]
Patient Fee Revenue, net of contractual allowances and discounts	$ 1,786	$ 1,787	$ 3,109	$ 3,881

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share - (Details 1) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Basic Numerator: Net income available to common stockholders	$ 1,964	$ 3,759	$ 5,099	$ 7,865
Weighted Average Number of Shares Outstanding, Basic	6,686	6,437	6,696	6,448
Income (Loss) from Continuing Operations, Per Basic Share	$ 0.31	$ 0.58	$ 0.81	$ 1.22
Common Class C [Member]
Basic Numerator: Net income available to common stockholders	$ 31	$ 59	$ 83	$ 125
Weighted Average Number of Shares Outstanding, Basic	383	383	383	383
Income (Loss) from Continuing Operations, Per Basic Share	$ 0.08	$ 0.16	$ 0.22	$ 0.33
Weighted Average Number of Shares Outstanding, Diluted	383	383	383	383
[custom:ConvertibleClassCStock]	0	0	0	0
[custom:WeightedAverageNumberOfDilutedEarningsPerShare]	383	383	383	383
Earnings Per Share, Diluted	$ 0.08	$ 0.16	$ 0.22	$ 0.33
Common Stock [Member]
Basic Numerator: Net income available to common stockholders	$ 1,840	$ 3,525	$ 4,775	$ 7,375
Weighted Average Number of Shares Outstanding, Basic	6,303	6,437	6,313	6,448
Income (Loss) from Continuing Operations, Per Basic Share	$ 0.29	$ 0.55	$ 0.76	$ 1.14
Weighted Average Number of Shares Outstanding, Diluted	6,303	6,437	6,313	6,448
[custom:ConvertibleClassCStock]	128	128	128	128
[custom:WeightedAverageNumberOfDilutedEarningsPerShare]	6,431	6,565	6,441	6,576
Earnings Per Share, Diluted	$ 0.29	$ 0.54	$ 0.74	$ 1.12

SUMMARY OF SIGNIFICANT ACCOUN_6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) shares in Thousands, $ in Thousands	6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock		128
[custom:RightToUseAssetToIntangibleAsset]	$ 1,300
Increase (Decrease) in Operating Lease Liability	1,700
Operating Lease, Payments	1,100
Income Tax Expense (Benefit), Intraperiod Tax Allocation	$ 116

ACCOUNTS RECEIVABLE, MEDICAL _3

ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Jun. 30, 2024
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	$ 3,390	$ 4,035
Accounts receivable - related party	60
Medical receivable	23,496	23,992
Management and other fees receivable	42,485	41,954
Management and other fees receivable from related medical practices (“PC’s”)	9,677	9,865
Accounts Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	3,663	4,201
Accounts receivable - related party	60
Medical receivable	23,496	23,992
Management and other fees receivable	55,148	54,324
Management and other fees receivable from related medical practices (“PC’s”)	16,666	15,975
Doubtful [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	273	166
Accounts receivable - related party
Medical receivable
Management and other fees receivable	12,663	12,370
Management and other fees receivable from related medical practices (“PC’s”)	$ 6,989	$ 6,110

ACCOUNTS RECEIVABLE, MEDICAL _4

ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Future Revenue (Details 1) $ in Thousands	Dec. 31, 2024 USD ($)
Receivables [Abstract]
Construction Contractor, Receivable, Excluding Contract Retainage, Year Two	$ 677
Construction Contractor, Receivable, Excluding Contract Retainage, Year Three	242
Construction Contractor, Receivable, Excluding Contract Retainage, Year Four	87
Construction Contractor, Receivable, Excluding Contract Retainage, Year Five	44
Construction Contractor, Receivable, Excluding Contract Retainage	$ 1,050

ACCOUNTS RECEIVABLE, MEDICAL _5

ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Jun. 30, 2024
Receivables [Abstract]
Increase (Decrease) in Accounts and Other Receivables			$ 724		$ 830
[custom:PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims]	58.20%	54.40%	59.30%	57.50%
[custom:PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims1]	72.50%	71.70%	72.20%	71.80%
[custom:PercentageOfConsolidatedNetRevenueFromManagementFees]	12%	11.80%	12%	11.70%

OPERATING & FINANCING LEASES -

OPERATING & FINANCING LEASES - Lease Payments (Details) $ in Thousands	Dec. 31, 2024 USD ($)
Operating Lease Payments [Member]
2025	$ 5,584
2026	5,388
2027	5,371
2028	5,019
2029	4,876
Thereafter	26,841
Present value discount	(14,893)
Operating Lease, Liability	38,186
Financing Lease Payments [Member]
2025	244
2026	244
2027	61
2028	0
2029	0
Thereafter	0
Present value discount	(15)
Finance Lease, Liability	$ 534

OPERATING & FINANCING LEASES (D

OPERATING & FINANCING LEASES (Details 1)	Dec. 31, 2024
Operating And Financing Leases
Operating Lease, Weighted Average Remaining Lease Term	10 years 7 months 6 days
Finance Lease, Weighted Average Remaining Lease Term	2 years 1 month 6 days
Operating Lease, Weighted Average Discount Rate, Percent	6.50%
Finance Lease, Weighted Average Discount Rate, Percent	3.60%

OPERATING & FINANCING LEASES _2

OPERATING & FINANCING LEASES (Details 2) - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Operating And Financing Leases
Operating lease cost	$ 3,190	$ 2,865
Finance lease cost:
Depreciation of leased equipment	100	100
Interest on lease liabilities	5	14
Total finance lease cost	$ 105	$ 114

OPERATING & FINANCING LEASES _3

OPERATING & FINANCING LEASES (Details 3) - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Operating And Financing Leases
Operating cash flows from operating leases	$ 2,541	$ 3,164
Financing cash flows from financing leases	122	122
Right-of-use and equipment assets obtained in exchange for lease obligations:
Operating leases	$ 359	$ 1,212

INVENTORIES - Inventories (Deta

INVENTORIES - Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Jun. 30, 2024
Inventory Disclosure [Abstract]
Purchased parts, components and supplies	$ 2,583	$ 2,524
Work-in-process	275	191
Total Inventories	$ 2,858	$ 2,715

OTHER INTANGIBLE ASSETS (Detail

OTHER INTANGIBLE ASSETS (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2024	Jun. 30, 2024
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount intangible assets	$ 21,595	$ 20,315
Accumulated amortization intangible assets	(18,188)	(17,445)
Net carrying amount intangible assets	$ 3,407	$ 2,870
Software and Software Development Costs [Member]
Finite-Lived Intangible Assets [Line Items]
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life	5 years	5 years
Gross carrying amount intangible assets	$ 7,005	$ 7,005
Accumulated amortization intangible assets	(7,005)	(7,005)
Net carrying amount intangible assets
License [Member]
Finite-Lived Intangible Assets [Line Items]
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life	3 years
Gross carrying amount intangible assets	$ 1,260
Accumulated amortization intangible assets	(567)
Net carrying amount intangible assets	$ 693
Patents And Copyrights [Member]
Finite-Lived Intangible Assets [Line Items]
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life	15 years	15 years
Gross carrying amount intangible assets	$ 5,280	$ 5,260
Accumulated amortization intangible assets	(4,180)	(4,104)
Net carrying amount intangible assets	$ 1,100	$ 1,156
Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life	7 years	7 years
Gross carrying amount intangible assets	$ 4,150	$ 4,150
Accumulated amortization intangible assets	(4,150)	(4,150)
Net carrying amount intangible assets	$ 0	$ 0
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life	20 years	20 years
Gross carrying amount intangible assets	$ 3,900	$ 3,900
Accumulated amortization intangible assets	(2,286)	(2,186)
Net carrying amount intangible assets	$ 1,614	$ 1,714

OTHER INTANGIBLE ASSETS (Deta_2

OTHER INTANGIBLE ASSETS (Details 1) - USD ($) $ in Thousands	Dec. 31, 2024	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Finite-Lived Intangible Asset, Expected Amortization, Year One	$ 723
Finite-Lived Intangible Asset, Expected Amortization, Year Two	650
Finite-Lived Intangible Asset, Expected Amortization, Year Three	321
Finite-Lived Intangible Asset, Expected Amortization, Year Four	317
Finite-Lived Intangible Asset, Expected Amortization, Year Five	314
Finite-Lived Intangible Asset, Expected Amortization, after Year Five	1,082
Intangible Assets, Net (Excluding Goodwill)	$ 3,407	$ 2,870

OTHER INTANGIBLE ASSETS (Deta_3

OTHER INTANGIBLE ASSETS (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Patents And Copyrights [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 37	$ 43	$ 76	$ 86
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 50	$ 50	$ 100	$ 100

OTHER CURRENT LIABILITIES - Oth

OTHER CURRENT LIABILITIES - Other Current Liabilities - (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Jun. 30, 2024
Payables and Accruals [Abstract]
Accrued salaries, commissions and payroll taxes	$ 1,541	$ 4,678
Sales tax payable	183	197
Federal and state income taxes payable		1,461
Self-funded health insurance reserve	168	121
Software Licenses	252
Other general and administrative expenses	1,768	1,484
Other Current Liabilities	$ 3,912	$ 7,941

SEGMENT AND RELATED INFORMATI_3

SEGMENT AND RELATED INFORMATION - Summarized Segments - (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Revenue from External Customer [Line Items]
Net revenues from external customers	$ 24,950	$ 25,386	$ 49,910	$ 51,224
Inter-segment net revenues	294	254	583	508
(Loss) Income from operations	2,435	4,885	7,041	11,456
Depreciation and amortization	1,235	1,220	2,298	2,415
Capital expenditures	754	133	2,572	212
Manufacturing And Service Of M R I Equipment [Member]
Revenue from External Customer [Line Items]
Net revenues from external customers	1,829	1,861	3,986	3,917
Inter-segment net revenues	294	254	583	508
(Loss) Income from operations	(1,291)	(993)	(2,335)	(1,731)
Depreciation and amortization	54	60	103	121
Capital expenditures	23	4	95	20
Health Care, Other [Member]
Revenue from External Customer [Line Items]
Net revenues from external customers	23,121	23,525	45,924	47,307
Inter-segment net revenues	0	0	0	0
(Loss) Income from operations	3,726	5,878	9,376	13,187
Depreciation and amortization	1,181	1,160	2,195	2,294
Capital expenditures	$ 731	$ 129	$ 2,477	$ 192

SUPPLEMENTAL CASH FLOW INFORM_2

SUPPLEMENTAL CASH FLOW INFORMATION (Details Narrative) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Dec. 31, 2024	Dec. 31, 2024	Dec. 31, 2023
Supplemental Cash Flow Elements [Abstract]
Interest Paid, Excluding Capitalized Interest, Operating Activities		$ 14	$ 58
Income Taxes Paid		2,473	150
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability		$ 359	$ 1,212
[custom:RateOfInterestSold]	0.197%
Conversion of Stock, Amount Converted	$ 132,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Jun. 30, 2024	Sep. 26, 2022
Stock Repurchased During Period, Value	$ 926	$ 1,171	$ 1,341	$ 1,885
Share Repurchase Program, Remaining Authorized, Amount	3,392		3,392
Liability for Claims and Claims Adjustment Expense	150		150
Self Insurance Reserve	$ 168		$ 168		$ 86
Board of Directors Chairman [Member]
Share Repurchase Program, Authorized, Amount						$ 9,000
Stock Repurchased During Period, Shares			84	116
Stock Repurchased During Period, Value			$ 1,342	$ 1,885
Stock Redeemed or Called During Period, Shares			125	123
Stock Redeemed or Called During Period, Value			$ 1,963	$ 2,005

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability	$ 762	$ 1,366	$ 2,011	$ 3,036
Extinguishment of Debt, Gain (Loss), Net of Tax	900		517
[custom:DeferredIncomeTaxComponent]	1,111		245
Deferred Tax Assets, Net of Valuation Allowance	6,113		6,113
Deferred Tax Liability Not Recognized, Amount of Unrecognized Deferred Tax Liability, Policyholders' Surplus	$ 371		$ 371
[custom:PercentageOfExciseTax]			1%
[custom:CorporateAlternativeMinimumTaxPercentage]			15%

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Jun. 30, 2024	Feb. 01, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
[custom:NetRevenues]			$ 5,975
[custom:ServiceAndMaintenancePrice-0]	$ 110,000		110,000			$ 70,000
[custom:ServiceAndRepairFees]	45	$ 28	90	$ 55
[custom:EmployeesFee]	68	0
Investment Income, Net	524	534	1,163	1,040
Magnetic Resonance Management [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Convertible Notes Payable		$ 577		$ 577
Derivative, Fixed Interest Rate		9%		9%
Investment Income, Net	$ 13		$ 26
Deferred Gain on Sale of Property					$ 577

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) shares in Thousands, $ in Thousands	Dec. 31, 2024 USD ($) shares
Subsequent Events [Abstract]
[custom:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchaseds-0] | shares	7
[custom:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount-0] | $	$ 108